Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Medical & Development Officer Ben Yong received new equity awards on March 10, 2026. He was granted a stock option for 210,000 shares of Common Stock at an exercise price of $10.19 per share, expiring in 2036.
He also received 46,670 restricted stock units (RSUs), each representing one share of Common Stock. The RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and the option vests in 48 substantially equal monthly installments from the same date, in each case contingent on continued service.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 3. This supplement, dated March 6, 2026, attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus dated September 10, 2025.
Shares outstanding were 80,032,823 as of March 2, 2026, reported in the Form 10-K; the supplement states the March 5, 2026 closing Nasdaq price of $9.89 per share.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical‑stage biotech formed via an August 2025 business combination between Helix Acquisition Corp. II and Legacy BBOT. The company focuses on cancers driven by KRAS and PI3Kα using three oral small‑molecule programs.
BBO‑8520, a dual ON/OFF KRAS G12C inhibitor, showed a 65% objective response rate (11/17 NSCLC patients) and 68% 6‑month progression‑free survival as of November 15, 2025, with no dose‑limiting toxicities or grade 3+ liver toxicity reported. Combination data with pembrolizumab showed tumor reductions in all eight evaluable patients.
BBO‑11818, a dual ON/OFF pan‑KRAS inhibitor, has early Phase 1 data including a confirmed partial response with 56% tumor reduction in pancreatic cancer. BBO‑10203, a PI3Kα “breaker,” showed tumor regressions in preclinical models and early clinical activity without hyperglycemia, supporting combination strategies across lung, colorectal, breast and pancreatic cancers. BBOT reports no approved products or revenue and highlights extensive development, regulatory, financing and market risks.
BridgeBio Oncology Therapeutics reported fourth quarter and full year 2025 results alongside major progress in its RAS-pathway cancer pipeline. The company ended 2025 with cash, cash equivalents and marketable securities of $425.5 million, which it expects will fund operations into 2028.
For 2025, research and development expenses rose to $121.2 million from $73.1 million, and general and administrative costs increased to $24.6 million from $7.8 million, reflecting expanded clinical activity and standalone operations after its SPAC transaction. Net loss widened to $134.0 million from $74.3 million.
Clinically, BBO-8520 showed a 65% objective response rate and 68% 6‑month progression-free survival in KRASG12C lung cancer, BBO-11818 delivered a confirmed partial response with a 56% tumor reduction in pancreatic cancer, and BBO-10203 achieved full target engagement with no observed hyperglycemia. Updated readouts across all three programs are expected in the second half of 2026.
BridgeBio Oncology Therapeutics, Inc. reported that it issued a press release sharing new clinical data for three innovative and differentiated RAS and PI3Kα pipeline programs.
The press release, dated January 7, 2026 and titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs,” is attached as an exhibit to this current report, with the full scientific and clinical details contained in that separate document.
BridgeBio Oncology Therapeutics, Inc. reported an update to its Chief Executive Officer and director’s stock option grant. On December 10, 2025, the company rescinded 1,114,400 stock options from an option grant originally dated October 2, 2025, as an exempt disposition to the issuer under Rule 16b-3.
After this change, 500,000 stock options from the original grant remain outstanding, each with an exercise price of $12.44 and an expiration date of October 1, 2035. The options vest in 48 substantially equal monthly installments beginning on the monthly anniversary of October 2, 2025, as long as the reporting person continues to provide service to the company on each vesting date.
BridgeBio Oncology Therapeutics (BBOT) filed its Q3 2025 10‑Q, highlighting a post‑de‑SPAC balance sheet and higher operating spend as programs scale. Cash and cash equivalents were $408.7 million and short‑term marketable securities were $59.5 million, for total liquidity of $468.3 million as of September 30, 2025. The company reported a net loss of $44.8 million for the quarter as operating expenses reached $49.2 million (R&D $35.1 million; G&A $14.1 million), with interest income of $3.4 million and $1.0 million from a transition services agreement.
BBOT completed its de‑SPAC on August 11, 2025, including a $260.9 million PIPE and $120.9 million from the SPAC trust, and ended the quarter with 79,196,710 shares outstanding. For the nine months, net loss was $95.2 million as the company advanced RAS and PI3K oncology programs and established public‑company infrastructure. Management states existing cash, cash equivalents, and marketable securities are expected to support operations for at least one year from issuance.
BridgeBio Oncology Therapeutics (BBOT) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company states the press release is provided under Item 2.02 and is being furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act. The filing includes Exhibit 99.1 (the press release dated November 12, 2025) and Exhibit 104 (the cover page Inline XBRL data).
BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.
The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.
After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.
BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.
The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.
After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.
BridgeBio Oncology Therapeutics, Inc. filed a Form S-8 to register securities under several employee benefit plans following corporate changes that include a domestication to Delaware and a name change. The filing discloses that TheRas, Inc. merged into a Merger Sub, leaving TheRas as a direct, wholly owned subsidiary, and that an Inducement Plan was adopted by the board under Nasdaq Rule 5635(c)(4) without stockholder approval. The registration references prior filings including the Form 10-K for year ended December 31, 2024 and subsequent 10-Qs, and incorporates the company’s Certificate of Incorporation and Bylaws by reference. Exhibits listed include the 2025 equity plans, the 2016 TheRas plan, legal opinions, auditor consents, and a filing-fee table. Signature blocks show directors and dates of October 10, 2025.